Effect of Ecopipam, a Selective Dopamine-1 Receptor Antagonist, on Tic Characteristics as Assessed by the YGTSS: Results from the Phase IIb (D1AMOND) Randomized, Double-blind, Placebo-controlled Clinical Trial in Tourette Syndrome (S30.009)

Assess the effect of ecopipam treatment on motor and phonic/vocal tic characteristics: number, frequency, intensity, complexity, and interference comprising the Yale Global Tic Severity Scale-Total Tic Score (YGTSS-TTS) in subjects ages 6 to <18 years with Tourette Syndrome (TS).